MedicGo
Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient.
Metadata
Journallung cancer4.702Date
2020 May 30
5 months ago
Type
Case Report
Volume
2020-08 / 146 : 362-365
Author
Ito M 1, Kanda S 2, Yoshida T 1, Okuma Y 1, Jo H 1, Fukuhara S 3, Maeshima AM 4, Ohe Y 1
Affiliation
  • 2. Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan. Electronic address: [email protected]
  • 3. Department of Hematology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
  • 4. Department of Diagnostic Pathology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
Doi
PMIDMESH
Abstract
OBJECTIVES: Immune checkpoint inhibitors (ICIs) have shown antitumor activity against a wide variety of malignancies. ICI-induced immune-related thrombocytopenia is a rare immune-related adverse event (irAE). Little is known about the treatment of refractory immune-related thrombocytopenia in non-small cell lung cancer (NSCLC) patients treated with pembrolizumab.
RESULTS: We report the case of a patient with advanced NSCLC complicated by pembrolizumab-induced refractory immune-related thrombocytopenia who showed remarkable improvement in the thrombocytopenia in response to eltrombopag olamine treatment.
CONCLUSION: Eltrombopag olamine can be a viable treatment option for refractory pembrolizumab-induced immune-related thrombocytopenia in an NSCLC patient.
Keywords: eltrombopag olamine immune-related thrombocytopenia non-small cell lung cancer pembrolizumab rituximab
Fav
Like
Download
Share
Export
Cite
4.7
Lung Cancerlung cancer
Metadata
LocationIreland
FromELSEVIER IRELAND LTD

No Data

© 2017 - 2020 Medicgo
Powered by some medical students